CEO Brent Guerisoli received total compensation of approximately $3.74 million in 2025, which is reasonable for a CEO of a $1.1 billion healthcare services company that grew adjusted earnings significantly and whose stock rose roughly 113% over three years. The pay structure is heavily performance-driven — the majority of the CEO's pay came from a formula-based annual incentive program tied to pre-established adjusted earnings targets, clinical quality metrics, and governance measures, with a portion paid in restricted stock, and a multi-year vesting stock option grant, meaning fixed salary represents a small fraction of total pay. The company has a meaningful clawback policy and the pay-for-performance alignment check passes because PNTG's 3-year stock return of +113.1% tracks closely with the peer group median return of +108.9%, confirming that above-benchmark incentive payouts are justified by shareholder outcomes.

Deloitte's non-audit-related fees for 2025 — audit-related fees of $1,147,704 plus other fees of $1,895, totaling approximately $1,149,599 — represent about 75% of the core audit fee of $1,535,000, which exceeds the 50% threshold in the policy. This elevated ratio raises concerns about auditor independence because the financial relationship between the company and its auditor extends well beyond the core audit work. Deloitte's tenure of approximately seven years does not trigger the 25-year concern, and no material restatements were identified, but the non-audit fee ratio alone is sufficient to warrant a negative vote.